Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2010

View Archived Issues

FV-60135-02 ameliorates retinal vascular damage in diabetic rats

SERM GTx-822 prevents oxidative stress

Promising clinical data disclosed on ATI-7505 in CiC

ALKS-27 improves lung function in COPD patients

Promising phase II data presented on NVA-237 in COPD

Pain Therapeutics discovers new mu opioid receptor agonists

New PKD inhibitor CRT-0066101 inhibits pancreatic cell growth

Boston Scientific begins trial to compare Promus Element and Xience Prime stents

Presidio selects HCV NS5A inhibitor PPI-1301 as clinical candidate

CoDa releases phase II efficacy data on Nexagon in venous leg ulcers

Schering claims new gamma-secretase modulators

Wyeth describes new liver X receptor ligands

Bayer Schering identifies new MEK 1 inhibitors

A study of the interactions between dextromethorphan/quinidine, paroxetine and memantine

Interim phase IIa data analysis on Trigemina's TI-001 in chronic daily headache

Vertex reports on phase III ADVANCE trial in HCV infection

GTx reports phase III data on toremifene in prostate cancer

Enrollment opened in phase III Reolysin trial in head and neck cancers

Cytochroma reports phase I/II data on CTAP-101 in CKD-associated hyperparathyroidism

Stem Cell Therapeutics reports on modified REGENESIS stroke trial

OccuLogix changes corporate name to TearLab

FDA approves Lumizyme for late-onset Pompe's disease

FDA grants priority review to Vivitrol sNDA for opioid dependence

Phase IIb trial of Epicept NP-1 in CPN reaches enrollment target

Advanced BioScience and Hawaii Biotech partner on dengue vaccine development

Nippon Boehringer Ingelheim and Astellas extend telmisartan collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...